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Background: Our previous work demonstrated that ectopic expression of interferon regulatory factor 4 binding
protein (IBP) was correlated with the malignant behaviour of human breast cancer cells. The mechanisms
controlling differential expression of IBP in breast cancer still remain unknown.
Results: To investigate the mechanism of IBP dysregulation in breast cancer, we identified IBP was a novel p53
target gene. IBP expression was negatively regulated by wild-type p53 and was p53 dependently suppressed by
DNA damage agent cisplatin. Furthermore, high levels of IBP were found to decrease cisplatin-induced growth
suppression and apoptotic cell death, which was associated with decreased p53 activity and imbalanced Bcl-2
family member expression.
Conclusions: IBP is a novel p53 target gene which suppresses cisplatin-mediated apoptosis of breast cancer cells
via negative feedback regulation of the p53 signalling pathway, suggesting IBP may serve as a target for
pharmacologic intervention of breast cancer resistant to cisplatin therapy.
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Since its discovery over 30 years ago, p53 has been
shown to play a key role in mediating cell responses to
stress. p53 primarily accomplishes this by inducing or
repressing a number of genes involved in cell cycle ar-
rest, senescence, apoptosis, DNA repair, and angiogen-
esis [1]. Among the roles of p53, its tumor-suppression
activity is associated with its ability to function as a tran-
scriptional master regulator [2]. The identification of
additional p53 target genes is steadily progressing and
may elucidate the mechanisms by which p53 exerts its
tumour-suppression activity.
Breast cancer is the most frequent cancer in women.
An estimated 1.15 million new cases of breast cancer
were identified in 2002. In China, breast cancer registries
record annual incidence increases of 3% to 4% [3]. Gen-
etic studies have revealed that at least one third of non-
familial breast cancers contain mutations in p53 [4], and* Correspondence: chuminhu@163.com
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reproduction in any medium, provided the or1,400 p53 mutations have been identified in breast can-
cer [5]. Efficacy of p53 activity represents a vulnerable
link in the barriers to tumorigenesis in the breast epithe-
lium [6]. In addition to its role in tumorigenesis, p53
also affects the effect of platinum therapy [7]. Previous
studies have shown that the p53 pathway is inactivated
in cisplatin-resistant MCF-7 breast cancer cells [8].
The Interferon regulatory factor 4 binding protein (IBP)
gene (NM_022047), also known as DEF6 or SLAT, has
been mapped to human chromosome 6p21.31 and is
centromeric to the MHC locus [9]. IBP is broadly
expressed in immune cells and can be detected in both
T- and B-cell compartments. In the immune system, IBP
functions as a guanine nucleotide exchange factor (GEF),
which is an upstream activator of the Rho-family GTPases
activates the Rac1, RhoA and CDC42 GTPases [10,11],
modulates TCR-induced signalling events [12], and regu-
lates TLR4-mediated signalling [13]. Loss of IBP in mice
led to the spontaneous development of systemic auto-
immunity [14]. Studies have shown that IBP has functions
in other systems. IBP is expressed in muscle cells and influ-
ences myoblast differentiation [11]. It is one of the top fived. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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coma (EMC) from other sarcomas [15]. Our laboratory
reported that IBP was over-expressed in a considerable
proportion of human breast and colorectal cancers [16,17].
IBP and p53 protein levels were negatively correlated
among 107 breast cancer tissue samples [16]. The expres-
sion pattern of IBP, its transcriptional regulation, and espe-
cially the link between IBP and p53 in breast cancer are
poorly understood.
In the present study, we sought to better understand the
mechanisms controlling differential expression of IBP. We
found that IBP contains a noncanonical p53-binding site
in its 5′-flanking region. IBP expression was suppressed
when wild-type p53 was directly bound to IBP promoter.
Further, IBP was down-regulated by the DNA damage
agents in breast cancer cell lines. Breast cancer cells over-
expressing IBP were resistant to cisplatin-induced growth
suppression and apoptosis. IBP knockdown increased cis-
platin chemosensitivity and up-regulated p53 expression.
Our results demonstrate that IBP is a novel p53 target
gene which suppresses cisplatin-mediated apoptosis of
breast cancer cells via negative feedback regulation of the
p53 signaling pathway.
Results
p53 inhibits the transcriptional activity of the IBP
promoter
To investigate transcriptional regulation of IBP, we first
analyzed the 5′-flanking region of IBP gene. PROMO
bioinformatics analysis (http://alggen.lsi.upc.edu/) [18,19]
demonstrated that it contained two p53 binding sequences:
−231 to −225 (GGGCCTC) and −223 to −217 (CATG
CCC). The canonical p53-binding site was originally
defined as RRRCWWGYYY and contained a separation of
0 to 13 bp, where R = purine, Y = pyrimidine, and W = A
or T [20]. The noncanonical sequences were composed of
3/4 or 1/2 sites that are functional targets for p53 transacti-
vation [2,21]. As shown in Figure 1A, the IBP gene −231 to
−217 contained a putative noncanonical p53-binding site
with a 1/2 site. To examine whether the putative IBP p53-
binding site was functionally responsible for p53-dependent
transcription, we subcloned 5′-deletion mutants of the IBP
5′-flanking region into a luciferase expression vector pGL3-
basic, and fragment pIV (−294 to +60), which has the
strongest transcriptional activity (Figure 1B) and harbours
p53-binding site, was transiently transfected into HCT116
p53−/− or HCT116 p53+/+ (wild-type p53) cells. pIV exhib-
ited higher luciferase activity in p53 knockout HCT116
cells (Figure 1C). When pIV or pV was co-transfected with
an empty pCMV, pCMV-p53 or pCMV-p53R175H vector
into p53 null HCT116 cells, pCMV-p53 significantly
decreased the luciferase activity of pIV. pCMV-p53R175H,
which expressed a p53 mutant, did not affect pIV luciferase
activity (Figure 1D). Additionally, we infected HCT116p53−/− cells with Ad-p53 at increasing concentrations. pIV
exhibited a dose dependent luciferase activity decrease in
response to increased Ad-p53, while pV did not. And when
the putative p53-binding site (−231/-217) was deleted from
pIV, Ad-p53 did not significantly decrease the luciferase ac-
tivity (Figure 1E). These observations indicate that func-
tional p53 decreases the activity of the IBP promoter
through its putative p53-binding site.
p53 attenuates IBP expression
To further test whether p53 decreases IBP expression,
MCF-7 cells (wild-type p53) were infected with Ad-p53
or Ad-GFP (as a control). After 96 h IBP protein was
significantly decreased with increased p53 expression
(Figure 2A). To determine the effects of endogenous p53
on IBP expression, we treated MCF-7 cells with MDM2
antagonist Nutlin-3 [22] for 8 h. The IBP protein level
was dose-dependently attenuated (Figure 2B). And in
p53 null HCT116 cells, Nutlin-3 could not decrease IBP
expression (see Additional file 1). To determine whether
p53 was required for IBP suppression, p53-targeting
RNAi lentiviral particles and the p53 inhibitor pifithrin-
α [23] were used in MCF-7 cells. The knockdown of p53
in MCF-7 cells increased IBP expression (Figure 2C),
and an increased IBP protein expression was observed
with increasing doses of pifithrin-α (Figure 2D). p21,
which is a p53-responsive gene [24], was used as an in-
ternal control in these experiments. To test whether p53
regulates transcriptional level of IBP, quantitative RT-
PCR was performed. As shown in Figure 2E, Ad-p53
and Nutlin-3 decreased IBP expression, while pifithrin-α
and p53-targeting RNAi lentiviral particles increased IBP
expression. These results indicate that IBP expression is
directly associated with p53 activation and thus is a p53-
responsive gene.
p53 protein binds to IBP core promoter
To further investigate the ability of p53 to bind the puta-
tive p53-binding site, 30-bp oligonucleotides that were
complementary to the p53-binding site were synthesised,
and EMSA was performed using MCF-7 cell nuclear
extracts. Nuclear proteins from HCT116 p53−/− were
extracted as a negative control. Specific binding was
observed in MCF-7 and HCT116 p53+/+ cell extracts,
but it did not occur in the HCT116 p53−/− extracts. Un-
labelled oligonucleotides that were derived from the p53
consensus binding sites of p21 effectively competed with
the labelled IBP probe and vice versa. Addition of a p53
antibody to the reaction resulted in a supershift of the
labelled bands (Figure 3A). These results demonstrate
that p53 specifically binds to p53-binding site of the IBP
promoter in vitro.
Because p53 protein is able to bind to the IBP pro-
moter in vitro, we tested whether p53 can also bind to
Figure 1 p53 inhibits the transcriptional activity of the IBP promoter. (A) The putative p53-binding site that is located in the promoter
region of the IBP gene is shown. The −231 to −222 and −226 to −217 regions contain noncanonical 1/2 sites. (B) Schematic representations of
the five promoter-reporter constructs that contained different-length fragments that were cloned into pGL3-basic vector are shown. The
promoter-luciferase constructs or the promoterless vector was transiently transfected into HEK293 cells. The luciferase activity was normalised to
Renilla luciferase activity that was expressed by pRL-TK and is presented as the mean ± SD of triplicate experiments. (C) HCT116 p53−/− and
HCT116 p53+/+ cells were transfected with pIV, pV or pGL3-basic respectively. (D) IBP promoter construct pIV or pV was cotransfected with pCMV-
p53 or pCMV-p53R175H into HCT116 p53−/− cells. The cotransfection with the empty pCMV vector serves as a control. The right inset shows the
expression of IBP and p53 in infected HCT116 p53−/− cells. (E) HCT116 p53−/− cells were infected with Ad-p53 in the progressively increased
concentration. (+, 102; ++, 104; +++,106 plague-forming units). The right inset shows the expression of p53 in infected HCT116 p53−/− cells. Cells
were transfected with the IBP promoter constructs (pI, pIV, pV or −231/-217 deleted pIV).
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performed with a p53 antibody to precipitate chromatin
from doxorubicin treated MCF-7, HCT116 p53−/− and
HCT116 p53+/+ cells (Figure 3B). The precipitated DNA
was PCR-amplified using primers that flanked the p53-binding site in the IBP promoter, to produce an expected
156-bp product. When HCT116 p53+/+ and MCF-7 cells
were treated with 50 nmol/L doxorubicin, the amplified
band was increased. This result demonstrates that p53
protein also binds to the IBP promoter p53-binding site
Figure 2 p53 attenuates IBP expression. (A and C) The expression of IBP and p53 in MCF-7 cells were tested by Western blot after Ad-p53
infection at different time points (A) or p53 RNAi lentiviruses infection (C). Ad-GFP or p53 RNAi cont. was a respective control. (B and D) The
expression of IBP was detected by Western blot in MCF-7 cells treated with different concentrations of Nutlin-3 (B) or pifithrin-α (D). GAPDH and
p21 served as controls. (E) Real-time PCR analysis of the expression of IBP in MCF-7 cells treated with Ad-p53 (96 h), p53-RNAi, Nutlin-3(10 μmol/L
for 8 h ) or pifithrin-α (30 μmol/L for 24 h); GAPDH was used as a control. * , p < 0.01.
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direct transcriptional target of p53.
IBP is suppressed by DNA damaging agents
Because p53 may be an important mediator of che-
motherapeutic toxicity in breast cancer and is induced
by DNA damage as a sensor for damaged DNA, we
tested whether IBP expression was changed by DNA
damaging agents. Cisplatin suppressed IBP expression in
a dose-dependent manner in MCF-7 and ZR-75-1 cells
that express wild type p53 (Figure 4A). We also detected
IBP expression in MCF-7 cells 96h after cisplatin treat-
ment. IBP expression was suppressed by cisplatin in a
time-dependent manner within 96h (see Additional file
2). Furthermore, IBP was suppressed with the DNA
damaging agent doxorubicin both in MCF-7 and ZR-75-
1 cells (Figure 4B). To investigate the p53 dependence of
DNA damaging agent-mediated IBP inhibition, we used
p53 deleted HCT116 p53−/− cells. IBP was suppressed
with cisplatin in HCT116 p53+/+ cells, but was un-
affected in HCT116 p53−/− cells (Figure 4C). Similar
results were obtained in MCF-7 cells stably expressingp53 RNAi (Figure 4D). These data indicate that the sup-
pression of IBP by genotoxic stress in breast cancer cells
is p53 dependent.
IBP regulates the sensitivity to cisplatin-induced
apoptosis in MCF-7 cells
It has been shown that p53 pathway is inactive in
cisplatin-resistant MCF-7 breast cancer cells [8]. Since
IBP is correlated with the malignant behaviour of human
breast cancer cells [16] and is down-regulated by p53 and
DNA damaging agent in MCF-7 cells, we explored the im-
portance of IBP in the response of MCF-7 to cisplatin. We
first established stable IBP over-expressing (IBP/MCF-7)
and stable IBP knockdown MCF-7 cells (MCF-7/IBP-
RNAi) (Figure 5A). Subsequently, IBP/MCF-7, MCF-7/
IBP-RNAi and the corresponding control cells were
exposed to cisplatin, and cell growth were measured.
Over-expression of IBP increased proliferation and sur-
vival of MCF-7 cells, and IBP knockdown increased cis-
platin sensitivity of MCF-7 cells (Figure 5B). The IC50
values on IBP knockdown, IBP over-expression, RNAi-
control and pEGFP-C1 cells of cisplatin for 24 h were 6.96
Figure 3 Recruitment of the p53 protein to the IBP promoter.
(A) EMSA assay demonstrating the ability of p53 to bind the IBP
promoter in vitro. The binding reactions were performed with
nuclear extracts and various labelled oligonucleotides in the
presence of unlabelled probes or antibodies as indicated. HCT116
p53−/− nuclear proteins were extracted as a negative control. A p21
probe served as a positive control. The band was supershifted using
an antibody against p53. Mouse IgG served as a supershift negative
control. (B) ChIP assay was performed using an anti-p53 antibody to
test whether the p53 protein could bind the IBP promoter in
HCT116 p53+/+, HCT116 p53−/− and MCF-7 cells. Cells were treated
with 50 nmol/L doxorubicin for 8 h. Mouse IgG was used as a
negative control.
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12.57 ± 1.90 μg/ml, respectively (Figure 5C).
Therefore the decreased survival with cisplatin in MCF-
7/IBP-RNAi cells was in large part due to an increase cell
death. To confirm that IBP depletion increased cisplatin
induced apoptosis in MCF-7 cells, we tested PARP and
Annexin V-PI expression. When the cells were treated with
cisplatin for 24 h, more cleaved PARP was detected in the
MCF-7/IBP-RNAi cells (Figure 6A). In addition, MCF-7/
IBP-RNAi cells showed increased percentage of Annexin
V-PI positive cells 12 h after cisplatin treatment (Figure 6B).
These results demonstrate that IBP participates in the sup-
pression of cisplatin-induced apoptosis in MCF-7 cells.
IBP over-expression inactivates p53 pathway through AKT
Since IBP suppressed cisplatin induced apoptosis, we fur-
ther investigated the effect of IBP on cisplatin-induced
apoptotic signals. Stabilization and activation of wild type
p53 are critical for cisplatin-mediated apoptosis. We
tested whether the mechanism of IBP-induced cisplatinresistance was associated with p53 inactivation. Expres-
sion of p53 target gene p21 was used to monitor p53 path-
way activity. As shown in Figure 7A, the basal expression
of p53 in the IBP knockdown MCF-7 cells was markedly
elevated. The p21 expression was consistent with p53 ex-
pression in IBP-knockdown and IBP-over-expressing
MCF-7 cells. Furthermore, we detected cisplatin-induced
p53 phosphorylation at Ser-15. In IBP-knockdown cells,
increased level of phosphorylated p53 could be induced by
cisplatin, whereas lower level p53 Ser-15 phosphorylation
was detected in the IBP-over-expressing MCF-7 cells
(Figure 7B). This data suggests that IBP over-expression in
breast cancer cells decreases p53 accumulation and activa-
tion in response to cisplatin.
Members of the Bcl-2 family also are key players in
regulating apoptosis. The apoptotic process is regulated
by the ratio between Bax and its antiapoptotic counterpart
Bcl-2. It is also known that p53 negatively regulates Bcl-2
expression and that wild-type p53 neutralises the death-
protective function of Bcl-2 [25,26]. We tested Bcl-2 and
Bax levels in IBP-over-expressing MCF-7 cells. The levels
of Bcl-2 were highly elevated in IBP-over-expressing
MCF-7 cells, and Bax expression was markedly reduced
(Figure 7A). This result shows that IBP regulates Bcl-2
family expression, and IBP disruptes p53 dependent apop-
totic pathway in breast cancer cells. Thus, there is a posi-
tive feedback loop between IBP and p53 pathway.
All p53 auto-regulatory loops are either induced by p53
at the transcriptional level or regulated by p53-induced
proteins [27]. It is known that AKT, which is closely asso-
ciated with DNA damage, induces the phosphorylation of
MDM-2 protein, which results in the translocation of
MDM-2 into the nucleus where it inactivates p53 [28].
Because the closest homolog of IBP, SWAP-70 [9], is
required for the proper activation of AKT [29], we tested
whether IBP may also activate AKT. We found high level
of AKT Ser-473 and MDM2 Ser-166 phosphorylation in
IBP-over-expressing MCF-7 cells (Figure 7C). Moreover,
when we treated IBP-over-expressing MCF-7 cells with
AKT inhibitor Ly294002 or wortmannin, p53 and p21 ex-
pression was elevated, and MDM2 phosphorylation was
decreased (Figure 7D). Further, p21 expression in IBP-
over-expressing MCF-7 cells treated with Ly294002 or
wortmannin for 24 h was quantified (see Additional file 3).
These results suggest that IBP may negatively regulate p53
activation through AKT in MCF-7 cells.
IBP regulates the sensitivity to cisplatin partly through
AKT/p53 pathway
Since IBP over-expression in turn negatively regulates p53
expression, We further investigated whether IBP regulates
the sensitivity to cisplatin in p53-dependent manner. In
stable MCF-7/IBP-RNAi cells, we inhibited p53 expres-
sion by p53 targeting RNAi lentiviral infection, then cells
Figure 4 IBP is p53 dependently suppressed in response to DNA damaging agents. The expression of IBP was tested with Western analysis.
(A) MCF-7 and ZR-75-1 which are human breast cancer cells with wild type p53 expression were treated with cisplatin for 24 h. (B) MCF-7 and
ZR-75-1 cells were treated with doxorubicin for 8 h. (C) HCT116 p53+/+ cells and HCT116 p53−/− cells were treated with cisplatin for 24 h. (D)
p53-RNAi MCF-7 cells were treated with cisplatin for different concentrations. Left was the RNAi effect of p53 in MCF-7 cells. GAPDH was used as
a control.
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Inhibition of p53 could decrease cisplatin sensitivity in
IBP-knockdown MCF-7 cells (Figure 8A). Moreover, we
established stable IBP-knockdown HCT116 p53−/− cells,
and measured cisplatin-induced cell growth suppression
in these cells by using CCK-8. As shown in Figure 8B, IBP
knockdown also increased cisplatin sensitivity of HCT116
p53−/− cells. Furthermore, in IBP-over-expressing MCF-7
cells, AKT inhibitors Ly294002 could attenuate cisplatin
resistance and increase cisplatin induced apoptosis
(Figure 8 C-D). These results suggest that IBP may impair
cisplatin chemosensitivity in breast cancer cells partly
through AKT/p53 pathway.
Discussion
IBP is a newly discovered protein aberrantly expressed
in breast cancer cells. We found that IBP promotes the
proliferation and migration of breast cancer cells and its
expression is negatively correlated with p53 levels [16].
Previous studies have shown the role of Lck in IBP acti-
vation in T lymphoma cells [12]. However, little is
known about the regulation of IBP expression, particu-
larly in breast cancer. Because previous studies haveshown that the activity of Rac1 (a downstream molecule
of IBP) is inversely regulated by functional p53 [30,31],
we investigated whether p53 could regulate IBP in breast
cancer cells. Here we have identified IBP as a novel p53
target gene. The inhibition of IBP expression corre-
sponded with increased p53 expression, and the induc-
tion of IBP was related to p53. p53 could bind to IBP
promoter in MCF-7 cells. The present results clearly in-
dicate that inactivation of wild-type p53 at least partially
explains the aberrant IBP expression in breast cancer.
It was previously reported that p53 could transactivate
genes from a noncanonical consensus 1/2-site or 3/4-
sites that contain a 1/4-site that is adjacent to a 1/2-site
or a 1/4-site and is separated from a 1/2-site by a 5-nt
spacer [32]. We have shown for the first time that IBP
promoter region possesses a noncanonical repressing
p53-binding site. We identified that IBP promoter con-
tains a “perfect” p53 half site, which contains a CATG
core motif. It is known that the C and G positions are
essential for the function of the p53-binding site, and
the presence of an “AT” as the “WW” dinucleotide is
associated with the high activity of a half site [2,33].
Ren’s group reported that CATG core was an activating
Figure 5 IBP regulates sensitivity to cisplatin in MCF-7 cells. (A) IBP expression was analyzed by Western blot in stable IBP-over-expressing
MCF-7 cells and IBP-knockdown MCF-7 cells. C1/MCF-7 and MCF-7/RNAi-cont. cells were respective control cells. (B) Cells were treated with
increasing cisplatin concentrations, and their proliferation rates were measured with a CCK-8 assay. (C) Cisplatin IC50 values were determined by
CCK cell survival assays. In the columns, the mean was derived from at least three independent experiments. A statistical analysis was performed
using Student’s t test. *, p < 0.05, significant.
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could modulate p53 function to become repressive, and
repressing p53 response elements had a much higher
frequency of noncanonical nucleotides in the position
immediately adjacent to the CWWG motif [34]. The
triplet flanking sequences in the p53-binding site of IBP
promoter also differ from the canonical p53-binding site
motif. However, whether the triplet flanking sequences
in the half p53-binding site or the 1/4-site that is adja-
cent to a 1/2-site modulate the p53 response element
behaviour in IBP promoter, needs further investigation.
In addition, it has been shown that p53 mutants can also
transactivate gene expression at noncanonical sites
[32,33]. Noncanonical sequences may exhibit responsive-
ness to p53 in combination with other transcription fac-
tors, such as the estrogen receptor [33]. In this study,
although the role of the p53 mutants or the possible cofac-
tors in IBP transcription in breast cancer remains to be
determined, further experiments will elucidate the mech-
anism of aberrant IBP expression in breast cancer cells.
So far little information is available concerning the func-
tion of IBP, especially in breast cancer. IBP is a GEF related
to the Rho GTPases. Recent study showed a new function
for GEFs in the modulation of cell death after genotoxicstress [35]. It is also reported that Cdc42 activity down-
stream of IBP might regulate mammalian genomic stability
[36]. In the present study, we have shown that IBP is
decreased upon exposure to DNA damaging agents in a
p53 dependent manner. It is known that the status of p53
is associated with resistance to DNA-damaging therapies
[37,38]. p53 mutations are common in breast cancer cells
and p53 inactivation is an important cause for cisplatin re-
sistance [8]. p53 pathway plays an important role in DNA
damage mediated apoptotic signals. Here we further
demonstrated that IBP regulated cisplatin-mediated apop-
tosis in MCF-7 cells. IBP over-expression increased cis-
platin resistance in MCF-7 cells. The response to DNA
damaging agent and the mechanisms of cisplatin resistance
are complex and multifactorial. It is likely that IBP is one
of the mediators for a p53-dependent cisplatin response in
breast cancer cells. Mechanisms that inhibit the propaga-
tion of DNA damage signalling to the apoptotic machinery
are complex. We found that IBP over-expression in MCF-
7 cells suppressed the basal protein expression of p53 and
p21, attenuated p53 phosphorylation, changed the ratio be-
tween Bax and Bcl-2, and activated AKT. It is known that
in chemoresistant cells cisplatin induced p53 phosphoryl-
ation is attenuated, particularly on Ser15 and Ser20, and
Figure 6 IBP knockdown results in increased cisplatin-mediated apoptotic cell death. (A) After a 24 h cisplatin treatment, the cell lysates of
the MCF-7/IBP-RNAi cells and the control cells were prepared, and the cytoplasmic marker of apoptosis (cleaved PARP) was detected by western
blot. (B) MCF-7/IBP-RNAi cells and the control cells were treated with 2 μg/ml cisplatin to induce apoptosis. The apoptosis was detected at 12 h
after cisplatin treatment by Alexa fluor 647 conjugated Annexin V-PI assays.
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role in the transduction of p53-mediated apoptosis [39].
These results indicate that IBP plays a role in increased cis-
platin resistance in at least three aspects: the loss of p53
function, over-expression of antiapoptotic Bcl-2, and acti-
vation of the PI3K/AKT pathway. Although our data
explained in partly the mechanisms of IBP-mediated sup-
pression of breast cancer cell apoptosis in response to cis-
platin, whether this function is related to RhoGTPase (e.g.
Cdc42) is still unknown. Other study has shown that p53-
mediated reactive oxygen species (ROS) production could
also be a mechanism of cisplatin-induced apoptosis [40]. Itis clear that Rac1 is an important regulator of ROS produc-
tion [41,42]. Whether IBP regulates cisplatin resistance
through Rac1 and ROS remains to be confirmed. In
addition, it is interesting that our results also suggest that
IBP over-expression in breast cancer cells may possibly in-
duce a potential p53 regulatory feedback loop.
Conclusions
In summary, we provide evidence that IBP, which is a direct
target gene of p53, is inversely regulated by p53. We
observed that IBP over-expression decreases cisplatin-
mediated breast cancer cell apoptosis, while IBP suppression
Figure 7 IBP over-expression activates p53 pathway though AKT. (A) The relative basal expression levels of IBP, p53, p21, Bcl-2, and Bax in
the IBP-knockdown MCF-7 cells (IBP-RNAi) and IBP-over-expressing MCF-7 cells (IBP). (B) The expression of p53 Ser-15 phosphorylation was tested
in IBP-over-expressing MCF-7 cells and IBP knockdown cells treated with cisplatin for 24 h. (C) Western analysis of levels AKT Ser-473, MDM2 Ser-
166 phosphorylation in IBP-over-expressing MCF-7 cells and control cells. (D) The expression of MDM2 Ser-166 phosphorylation, p53 and p21
were detected in IBP-over-expressing MCF-7 cells treated with Ly294002 or wortmannin for 24 h. GAPDH served as a loading control.
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feedback regulator of p53. These observations promote our
understanding of the relationship between IBP signalling
and the p53 tumour suppressor. Therefore IBP may serve as
a target for pharmacologic intervention of breast cancer
resistant to cisplatin therapy.
Materials and methods
Cell lines
HEK293 cells and human breast cancer MCF-7 cells,
ZR-75-1 cells, were purchased from the Type Culture
Collection of the Chinese Academy of Sciences (Shang-
hai, China). The HCT116 p53−/− and HCT116 p53+/+
cell lines were gifts from Dr. Vogelstein (Johns Hopkins
University, USA) [43] and Dr. Zhihua Liu (Chinese
Academy of Medical Sciences and Peking Union Medical
College, China) [44]. MCF-7 cells were grown in MEM
medium that was supplemented with 10% foetal bovineserum, 1% non-essential amino acids and 10 μg/ml insu-
lin. ZR-75-1 cells were grown in RPMI-1640 medium
with 10% foetal bovine serum. HEK293 cells, HCT116
p53−/− and p53+/+ cells were maintained in DMEM that
was supplemented with 10% foetal bovine serum. All of
the cells were maintained in a humidified atmosphere
that contained 5% CO2 at 37°C.
Plasmid construction and mutagenesis
The −1807/+60, −979/+60, −640/+60, −294/+60 and
−116/+60 fragments of the human IBP gene (relative to
the transcriptional start site) were amplified from the
genomic DNA of MCF-7 cells by PCR using KOD poly-
merase (Toyobo). These amplified fragments were
inserted into the KpnI and HindIII restriction sites of
the pGL3-basic vector (Promega). The wild-type p53 ex-
pression plasmid, pCMV-p53, and the p53 mutant
plasmid, pCMV-p53R175H, were kindly provided by
Figure 8 (See legend on next page.)
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Figure 8 IBP regulates the sensitivity to cisplatin partly through AKT/p53 pathway. (A) In stable MCF-7/IBP-RNAi cells, cells were infected
with p53 targeting RNAi lentiviral or control lentiviral, and then treated with increasing cisplatin for 24 h. Cell proliferation rates were measured
with CCK-8 assay. (B) Stable IBP-knockdown HCT116 p53−/− cells were treated with cisplatin for 24 h and cell proliferation were measured. (C and
D) IBP over-expressing MCF-7 cells were treated with cisplatin and 10 μ mol/L Ly294002 for 24 h. Cell proliferation was measured by CCK-8 assay
(C). Cleaved PARP and AKT Ser-473 phosphorylation were detected by western blot (D).
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MutanBEST kit (TaKaRa) was used to introduce the p53
binding site into the IBP promoter deletion mutant. The
following mutagenic primers were used: forward 5′-CG
GGAGCCACGTGGATACAG-3′, reverse 5′-TTTTAGA
AGCCTCCTCAGACCC-3′. The pEGFP-C1-IBP expres-
sion plasmid was a gift from Dr. Alessandra B. Pernis
(Columbia University, USA). All of the constructs were
confirmed by DNA sequencing.
Adenovirus infection and cell treatment
Adenovirus(Ad)-p53 was purchased from Shenzhen
SiBiono GeneTech Co. [44]. Ad-GFP was purchased
from Shanghai Sunbio Medical Biotechnology Co. The
cells were treated with different concentrations of doxo-
rubicin (Sigma-Aldrich) for 8 h, Nutlin-3 (Beyotime) for
24 h and pifithrin-α (Beyotime) for 24 h. The cisplatin
(Sigma-Aldrich) concentrations and experimental details
are described in the text and figure legends. The cells
were treated with Ly294002 (Beyotime) or wortmannin
(Beyotime) for 24 h.
RNA interference
To knockdown IBP expression, double-stranded DNA
oligonucleotides (forward, 5′-TGCTGTTCATCTGGA
CATTCCAGTGTGTTTTGGCCACTGACTGACACAC
TGGAGTCCAGATGAA-3′ and reverse, 5′-CCTGTT
CATCTGGACTCCAGTGTGTCAGTCAGTGGCCAAA
ACACACTGGAATGTCCAGATGAAC-3′) were subcloned
into pcDNA™6.2-GW/EmGFPmiR (Invitrogen) using
the BLOCK-iT Pol II miR RNAi Expression Vector
Kit (Invitrogen). The RNAi plasmid or control plas-
mid, which contained a non-specific sequence, was
transfected into MCF-7 cells. Lipofectamine 2000
(Invitrogen) was used as the transfection reagent.
The growth medium was supplemented with blasti-
cidin (10 μg/ml, Invitrogen), which was used to se-
lect for blasticidin-resistant transfectants. For the
p53 knockdown, double-stranded DNA oligonucleo-
tides (forward, 5′-CCGGGACTCCAGTGGTAATC
TACTTCAAGAGAGTAGATTACCACTGGAGTCTTT
TTG-3′ and reverse, 5′-AATTCAAAAAGACTCCAGT
GGTAATCTACTCTCTTGAAGTAGATTACCACTGGA
GTC-3′) were subcloned into pMagic 1.1 and packaged
into lentivirus particles (Shanghai Sunbio Medical Bio-
technology Co.). One day after infection, the cell-growth medium was supplemented with puromycin
(2 μg/ml, Invitrogen) to select stable transfectants.Luciferase reporter assays
Luciferase reporter assays were performed using the
Dual-LuciferaseW Reporter Assay System (Promega).
Cells were seeded in 24-well plates (1.0 × 105 cells/well)
and transfected together with a promoter-reporter gene
vector and the pRL-TK Renilla luciferase vector. After
48 h of transfection, the cells were harvested and ana-
lysed according to the manufacturer’s instructions. The
luciferase activities were normalised to the Renilla luci-
ferase activity of the internal control.Western blotting
Cell lysates were prepared in RIPA buffer (Beyotime).
Whole-cell lysates were separated on a 10% SDS-PAGE gel
and transferred onto polyvinylidene difluoride (PVDF)
membranes (Millipore). The membranes were blocked for
1 h at 37°C in 5% non-fat milk/TBST and were then incu-
bated with primary antibodies overnight at 4°C. Antibodies
against IBP (produced as described previously) [16], p53
(sc-126, Santa Cruz), p21 (3733–1, Epitomics), PARP
(9532, Cell Signaling), phospho-p53(Ser15) (9284, Cell Sig-
naling), Bcl-2 (1017–1, Epitomics), Bax (AB026, Beyotime),
phospho-AKT(Ser473) (4060, Cell Signaling), AKT(4691,
Cell Signaling),phospho-MDM2(Ser166) (3521, Cell Signal-
ing), MDM2(sc-965, Santa Cruz) and GAPDH (AG019,
Beyotime) were used. The membrane was then rinsed in
TBST and incubated with various secondary antibodies for
2 h at 25°C. Immunoreactive bands were visualised with a
chemiluminescent HRP substrate (Millipore).Quantitative RT-PCR
Total RNA was isolated using TRIzol (Invitrogen), and
1 μg of isolated RNA was reverse transcribed to generate
cDNAs (TaKaRa). Amplification was performed by using
SYBR Premix Ex Taq II (TaKaRa). The primers used for
amplification included the following: IBP forward, 5′-GA
GGGCTGACGAGGATGTGG-3′ and reverse, 5′-GCTG
GTGACCGGACGCTTAT-3′; and GAPDH forward, 5′-A
ATCCATCACCATCTTCCA-3′ and reverse, 5′-TGGAC
TCCACGACGTACTCA-3′. GAPDH mRNA levels were
determined as an internal control.
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Nuclear extracts were prepared in hypertonic buffer
(420 mM NaCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.2 mM
EDTA, 0.5 mM PMSF, 25% glycerol, 5 μg/ml aprotinin,
5 μg/ml phenanthroline, 3 μg/ml pepstatin A and 20 mM
HEPES). Double-stranded oligonucleotide probes that
were derived from the IBP gene promoter (sense strand,
5′-TAAAAGGGCCTCACATGCCCCGGGAGCCAC-3′)
and p21 gene promoter (sense strand, 5′-GGAAGAA
GACTGGGCATGTCTGGGCAGAGA-3′) [44] were la-
belled with γ-32P-ATP using T4 polynucleotide kinase.
The nuclear extracts (8 μg) were incubated with the
probe for 30 min at 30°C. The protein-DNA complexes
were resolved using non-denaturing PAGE and were
detected by autoradiography. For the cold probe compe-
tition assay, unlabelled probe was added to the nuclear
protein extracts one hour before the detection was per-
formed. In the supershift assay, 1 μl of an anti-p53 anti-
body (sc-126x, Santa Cruz) was incubated with the
nuclear extracts for 1 h at room temperature prior to the
addition of the radiolabeled probe and the implementa-
tion of PAGE.Chromatin immunoprecipitation assay (ChIP)
The ChIP assays were performed using an EZ-ChIPTM
Chromatin Immunoprecipitation Kit (Upstate) following
the manufacturer’s instructions. Briefly, cells were cross-
linked with 1% formaldehyde and a p53 antibody (sc-126,
Santa Cruz) or control IgG, which was used to precipitate
the crosslinked protein/chromatin. The DNA fragments
were analysed using PCR with a primer set (forward, 5′-T
TTTCCCTCAGCAAGCTGCGTCTGG-3′ and reverse,
5′-CTGCATGGGAACTGGGGACCAACTCT-3′) that
was designed to amplify the −305 to −150 region of the
IBP gene that harbours p53-binding site.Cell survival assays
A cell survival assay was performed in triplicate with a
Cell Counting Kit-8 (CCK-8, Beyotime). The cells were
seeded in 96-well plates at 5 × 103 cells/well (100 μl/
well) 24 h before the cisplatin treatment. The culture
medium was then replaced with fresh medium that con-
tained different concentrations of cisplatin, which ranged
from 0 to 32 μg/ml, and the cells were cultured in this
medium for 24 h. Following the incubation, 10 μl of
CCK-8 solution was added to each well, and after 1 h,
the absorbance value of each well was read at 450 nm.
The cell growth rate was calculated as the ratio of the
absorbance of the experimental well to that of the blank
well. The IC50 values (the drug concentration that
results in a 50% absorbance reduction compared to the
control) were calculated.Annexin V-PI flow cytometry assay
Flow cytometry assay was performed by using Caliber II
sorter and Cell Quest FACS system (BD Biosciences).
Alexa fluor 647 conjugated Annexin V (invitrogen) and
PI (Invitrogen) was incubated for 15 min according to
the manufacturer’s protocol. About 104 cells were mea-
sured per sample.
Additional files
Additional file 1: Figure S1. In HCT116 p53−/− cells, Nutlin-3 could not
decrease IBP expression. IBP expression was detected by western blot
when HCT116 p53−/− cells were treated with different concentration of
Nutlin-3 for 8 h.
Additional file 2: Figure S2. IBP expression is not increase in response
to cisplatin within 96 h in MCF-7 cells. IBP and p53 expression was
detected by western blot when MCF-7 cells were treated with 8 μg/ml
cisplatin continuously for 12 h to 96 h.
Additional file 3: Figure S3. Quantification analysis for p21 expression
in IBP-over-expressing MCF-7 cells treated with Ly294002 or wortmannin
for 24 h.
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